Staffan Hägg

5.5k total citations
99 papers, 3.8k citations indexed

About

Staffan Hägg is a scholar working on Toxicology, Psychiatry and Mental health and Geriatrics and Gerontology. According to data from OpenAlex, Staffan Hägg has authored 99 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Toxicology, 23 papers in Psychiatry and Mental health and 20 papers in Geriatrics and Gerontology. Recurrent topics in Staffan Hägg's work include Pharmacovigilance and Adverse Drug Reactions (25 papers), Pharmaceutical Practices and Patient Outcomes (20 papers) and Pharmaceutical studies and practices (14 papers). Staffan Hägg is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (25 papers), Pharmaceutical Practices and Patient Outcomes (20 papers) and Pharmaceutical studies and practices (14 papers). Staffan Hägg collaborates with scholars based in Sweden, Norway and United States. Staffan Hägg's co-authors include Olav Spigset, Anna K. Jönsson, Tom Mjörndal, Katja M. Hakkarainen, Rune Dahlqvist, Max Petzold, Johan Ahlner, Neil B. Ruderman, Michael Berger and Henrik Druid and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Biochemical Journal.

In The Last Decade

Staffan Hägg

97 papers receiving 3.5k citations

Peers

Countries citing papers authored by Staffan Hägg

Since Specialization

Citations

This map shows the geographic impact of Staffan Hägg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Staffan Hägg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Staffan Hägg more than expected).

Fields of papers citing papers by Staffan Hägg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Staffan Hägg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Staffan Hägg. The network helps show where Staffan Hägg may publish in the future.

Co-authorship network of co-authors of Staffan Hägg

This figure shows the co-authorship network connecting the top 25 collaborators of Staffan Hägg. A scholar is included among the top collaborators of Staffan Hägg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Staffan Hägg. Staffan Hägg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing Methods for Estimating Direct Costs of Adverse Drug Events 2017 ·Value in Health ·Hanna Gyllensten, Anna K. Jönsson, Katja M. Hakkarainen, Staffan Svensson, Staffan Hägg, Clas Rehnberg	6
2	The understanding of core pharmacological concepts among health care students in their final semester 2015 ·BMC Medical Education ·Patrik Aronsson, Shirley Booth, Staffan Hägg, Karin Kjellgren, (unknown), G. Tobin, Margareta Reis	15
3	In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia 2015 ·Therapeutic Drug Monitoring ·Karin Skoglund, Johan Richter, Ulla Olsson‐Strömberg, Jonas Bergquist, (unknown), S. J. Kumari A. Ubhayasekera, Svante Vikingsson, (unknown), Stina Söderlund, Anna Sandstedt, Anders Johnsson, (unknown), (unknown), Staffan Hägg, Curt Peterson, Kourosh Lotfi, Henrik Gréen	10
4	The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting 2015 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg, Anna K. Jönsson	15
5	Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis 2012 ·PLoS ONE ·Katja M. Hakkarainen, (unknown), Max Petzold, Staffan Hägg	223
6	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’ 2012 ·International Journal of Clinical Pharmacy ·Hanna Gyllensten, Katja M. Hakkarainen, Anna K. Jönsson, Karolina Andersson Sundell, Staffan Hägg, Clas Rehnberg, Anders Carlsten	10
7	Methods for Assessing the Preventability of Adverse Drug Events 2011 ·Drug Safety ·Katja M. Hakkarainen, Karolina Andersson Sundell, Max Petzold, Staffan Hägg	42
8	Effects of Cocoa Extract and Dark Chocolate on Angiotensin-converting Enzyme and Nitric Oxide in Human Endothelial Cells and Healthy Volunteers–A Nutrigenomics Perspective 2010 ·Journal of Cardiovascular Pharmacology ·Ingrid Persson, Karin Persson, Staffan Hägg, Rolf G. G. Andersson	47
9	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction 2009 ·British Journal of Clinical Pharmacology ·Johanna Strandell, Andrew Bate, Staffan Hägg, I. Ralph Edwards	41
10	Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden 2009 ·Pharmacoepidemiology and Drug Safety ·(unknown), Anna K. Jönsson, Barbro Gerdén, Staffan Hägg	57
11	Associations Between Venous Thromboembolism and Antipsychotics 2008 ·Drug Safety ·Staffan Hägg, Andrew Bate, (unknown), Olav Spigset	46
12	Incidence of fatal adverse drug reactions: a population based study 2007 ·British Journal of Clinical Pharmacology ·(unknown), Anna K. Jönsson, Olav Spigset, Henrik Druid, Staffan Hägg	238
13	IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION 2007 ·Clinical and Experimental Pharmacology and Physiology ·Stina Axelsson, Staffan Hägg, Andreas Eriksson, Tomas Lindahl, Per A Whiss	59
14	Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users 2004 ·Acta Obstetricia Et Gynecologica Scandinavica ·Eva Samuelsson, Staffan Hägg	34
15	[New antidepressive agents during pregnancy and lactation. Drug concentration should be monitored and the lowest possible dose administered]. 2004 ·PubMed ·Olav Spigset, Staffan Hägg	2
16	Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis 2003 ·International Clinical Psychopharmacology ·Staffan Hägg, (unknown), Olav Spigset	39
17	Adverse drug reactions as a cause for admissions to a department of internal medicine 2002 ·Pharmacoepidemiology and Drug Safety ·Tom Mjörndal, (unknown), Staffan Hägg, Martin Bäckström, Bengt‐Erik Wiholm, Anders Wåhlin, Rune Dahlqvist	165
18	Effect of caffeine on clozapine pharmacokinetics in healthy volunteers 2000 ·British Journal of Clinical Pharmacology ·Staffan Hägg, Olav Spigset, Tom Mjörndal, Rune Dahlqvist	50
19	Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis 2000 ·European Journal of Clinical Pharmacology ·Olav Spigset, Staffan Hägg, Bernd Stegmayr, Rune Dahlqvist	22
20	Commitment in Agent Cooperation, Applied to Agent-Based Simulation 1998 ·KTH Publication Database DiVA (KTH Royal Institute of Technology) ·Staffan Hägg	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact